Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hyloris Pharmaceuticals SA (HYL) Fair Value & Analysis

Healthcare · BE · Market cap €133M

Price€4.79
Fair Value€4.25
Upside-11.3%
Quality95/100
Evidence: Low Range €3.19 – €5.32

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Hyloris Pharmaceuticals SA (HYL) currently trades at €4.79, while our model-based Fair Value estimate is €4.25 — implying the stock looks roughly 11.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis. In addition, the company is involved in the development of Alenura for painful bladder syndrom…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Hyloris Pharmaceuticals SA (HYL) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €4.25 versus a price of €4.79 — about −11% (overvalued). Model-based estimate, not financial advice.
What is the fair value of HYL?
Our 21-model fair value for Hyloris Pharmaceuticals SA is €4.25 (as of Jun 24, 2026), built from audited fundamentals. The current price is €4.79.
What is the quality score of HYL?
Hyloris Pharmaceuticals SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.